| Literature DB >> 22258856 |
Willie M Greggs1,2, Christine L Clouser3,2, Steven E Patterson4,2, Louis M Mansky5,1,4,2,3.
Abstract
Feline leukemia virus (FeLV) is a gammaretrovirus that is a significant cause of neoplastic-related disorders affecting cats worldwide. Treatment options for FeLV are limited, associated with serious side effects, and can be cost-prohibitive. The development of drugs used to treat a related retrovirus, human immunodeficiency virus type 1 (HIV-1), has been rapid, leading to the approval of five drug classes. Although structural differences affect the susceptibility of gammaretroviruses to anti-HIV drugs, the similarities in mechanism of replication suggest that some anti-HIV-1 drugs may also inhibit FeLV. This study demonstrates the anti-FeLV activity of four drugs approved by the US FDA (Food and Drug Administration) at non-toxic concentrations. Of these, tenofovir and raltegravir are anti-HIV-1 drugs, while decitabine and gemcitabine are approved to treat myelodysplastic syndromes and pancreatic cancer, respectively, but also have anti-HIV-1 activity in cell culture. Our results indicate that these drugs may be useful for FeLV treatment and should be investigated for mechanism of action and suitability for veterinary use.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22258856 PMCID： PMC3542715 DOI： 10.1099/vir.0.039909-0
Source DB: PubMed Journal: J Gen Virol ISSN： 0022-1317 Impact factor: 3.891